Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 2
Submit an article Journal homepage
705
Views
11
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS

Xiaozhong Qiana Celgene Corporation, Summit, NJ, USA; View further author information
,
Meletios A. Dimopoulosb Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece; View further author information
,
Michael Amatangeloa Celgene Corporation, Summit, NJ, USA; View further author information
,
Chad Bjorklunda Celgene Corporation, Summit, NJ, USA; View further author information
,
Fadi Towfica Celgene Corporation, Summit, NJ, USA; View further author information
,
Erin Flynta Celgene Corporation, Summit, NJ, USA; View further author information
,
Katja C. Weiselc Department of Medicine, University Hospital of Tübingen, Tübingen, Germany; View further author information
,
Enrique M. Ociod Cancer Research Center (IBMCC-CSIC-USAL), University Hospital of Salamanca-IBSAL, Salamanca, Spain; View further author information
,
Xin Yua Celgene Corporation, Summit, NJ, USA; View further author information
,
Teresa Pelusoa Celgene Corporation, Summit, NJ, USA; View further author information
,
Lars Sternasa Celgene Corporation, Summit, NJ, USA; View further author information
,
Mohamed Zakia Celgene Corporation, Summit, NJ, USA; View further author information
,
Philippe Moreaue Hematology Department, University Hospital Hôtel‐Dieu, Nantes, FranceView further author information
&
Anjan Thakurtaa Celgene Corporation, Summit, NJ, USA; Correspondence[email protected]
View further author information
 show all
Pages 462-470 | Received 02 May 2018, Accepted 31 May 2018, Published online: 02 Aug 2018

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Oliver Van Oekelen, Samir Parekh, Hearn J. Cho, Nivetha Vishnuvardhan, Deepu Madduri, Joshua Richter, Chun Ip, Kenneth Lau, Erika Florendo, Ines S. Mancia, Joanne Thomas, Daniel Verina, Elaine Chan, Katarzyna Zarychta, Lisa La, Gina Strumolo, David T. Melnekoff, Violetta V. Leshchenko, Seunghee Kim-Schulze, Suzana Couto, Maria Wang, William E. Pierceall, Anjan Thakurta, Alessandro Laganà, Sundar Jagannath & Ajai Chari. (2020) A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia & Lymphoma 61:9, pages 2208-2215.
Read now
Elżbieta Iskierka-Jażdżewska, Federico Canzian, Anna Stępień, Alessandro Martino, Daniele Campa, Angelica Stein, Małgorzata Krawczyk-Kuliś, Malwina Rybicka-Ramos, Sławomira Kyrcz-Krzemień, Aleksandra Butrym, Grzegorz Mazur, Artur Jurczyszyn, Daria Zawirska, Norbert Grząśko, Waldemar Tomczak, Edyta Subocz, Marzena Wątek, Marcin Pasiarski, Marcin Rymko, Małgorzata Całbecka, Agnieszka Druzd-Sitek, Jan Walewski, Marcin Kruszewski, Małgorzata Raźny, Jan Maciej Zaucha, Marek Dudziński, Paweł Gaj, Tadeusz Robak, Krzysztof Warzocha & Krzysztof Jamroziak. (2020) Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium. Leukemia & Lymphoma 61:3, pages 699-706.
Read now

Articles from other publishers (9)

Ota Fuchs. (2023) Targeting cereblon in hematologic malignancies. Blood Reviews 57, pages 100994.
Crossref
Mateo Mejia Saldarriaga, Walaa Darwiche, David Jayabalan, Jorge Monge, Cara Rosenbaum, Roger N. Pearse, Ruben Niesvizky & Mark Bustoros. (2022) Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance. Frontiers in Oncology 12.
Crossref
Kristine Misund, Davine Hofste op Bruinink, Eivind Coward, Remco M. Hoogenboezem, Even Holth Rustad, Mathijs A. Sanders, Morten Rye, Anne-Marit Sponaas, Bronno van der Holt, Sonja Zweegman, Eivind Hovig, Leonardo A. Meza-Zepeda, Anders Sundan, Ola Myklebost, Pieter Sonneveld & Anders Waage. (2022) Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. Leukemia 36:7, pages 1887-1897.
Crossref
Byung-Hyun Lee, Ka-Won Kang, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Yong Park, Chul Won Choi & Byung Soo Kim. (2021) Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients. Frontiers in Oncology 11.
Crossref
Suvir Singh. (2021) Identifying Myeloma Patients at Risk of Lenalidomide or Pomalidomide Resistance at Relapse: A New Opportunity. Indian Journal of Medical and Paediatric Oncology 42:02, pages 180-181.
Crossref
Sarah Gooding, Naser Ansari-PourFadi TowficMaría Ortiz EstévezPhilip P. Chamberlain, Kao-Tai TsaiErin FlyntMarissa HirstDan RozellePaula Dhiman, Paola Neri, Karthik Ramasamy, Nizar Bahlis, Paresh Vyas & Anjan Thakurta. (2021) Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood 137:2, pages 232-237.
Crossref
Bachisio ZicchedduGiulia BianconFilippo BagnoliChiara De Philippis, Francesco Maura, Even H. RustadMatteo DugoAndrea DevecchiLoris De CeccoMarialuisa SensiCarolina TerragnaMarina Martello, Tina Bagratuni, Efstathios Kastritis, Meletios A. Dimopoulos, Michele CavoCristiana CarnitiVittorio MontefuscoPaolo CorradiniNiccolo Bolli. (2020) Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Advances 4:5, pages 830-844.
Crossref
Phoebe A. Huang, Shaunna L. Beedie, Cindy H. Chau, David J. Venzon, Sheryl Gere, Dickran Kazandjian, Neha Korde, Sham Mailankody, Ola Landgren & William D. Figg. (2019) Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide. Scientific Reports 9:1.
Crossref
Gang Lu, Stephanie Weng, Mary Matyskiela, Xinde Zheng, Wei Fang, Scott Wood, Christine Surka, Reina Mizukoshi, Chin-Chun Lu, Derek Mendy, In Sock Jang, Kai Wang, Mathieu Marella, Suzana Couto, Brian Cathers, James Carmichael, Philip Chamberlain & Mark Rolfe. (2018) UBE2G1 governs the destruction of cereblon neomorphic substrates. eLife 7.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.